BTK and B-cell chronic lymphocytic leukemia: SJF-620 showedpromise as an effective strategy for treating C481s mutant chroniclymphocytic leukemia (CLL).104 Furthermore,Sun’s research team introduced a new PROTAC strategy to degradeIbrutinib-resistant BTK specifically.105 With high efficiency and specificity, this approach successfullyovercame the acquired resistance that resulted from the BTK mutationC481s.105